What precautions should breastfeeding mothers take with lurbinectedin?

Understanding Lurbinectedin and Breastfeeding

Lurbinectedin is a chemotherapeutic agent used to treat certain types of cancer. As with any medication, there are potential risks associated with lurbinectedin that breastfeeding mothers should be aware of [1].

What is Lurbinectedin?

Lurbinectedin, also known as PM11803, is a synthetic molecule that works by targeting the transcription factor E2F, which is involved in cancer cell growth and proliferation [2]. It is administered intravenously and has been shown to be effective in treating several types of cancer, including small cell lung cancer and ovarian cancer.

Precautions for Breastfeeding Mothers

Breastfeeding mothers taking lurbinectedin may need to consider the potential risks to their baby. In animal studies, lurbinectedin was found to have teratogenic effects, including skeletal dysmorphia and cleft palate [3]. While the relevance of these findings to human breastfed infants is unclear, breastfeeding mothers may need to consider alternative arrangements for their baby's care.

Assessing the Risk

The FDA categorizes lurbinectedin as a pregnancy category D, indicating that there is evidence of risk based on animal studies, but the potential benefits may outweigh the risks in certain situations [4]. However, the FDA does not provide specific guidance on breastfeeding.

Alternatives and Considerations

In situations where breastfeeding mothers are taking lurbinectedin, healthcare providers may recommend alternative medications or arrangements for their baby's care. The decision to continue breastfeeding while taking lurbinectedin should be made on a case-by-case basis, taking into account the individual mother's situation and the potential risks to the baby.

Recommendations

Based on the available evidence, breastfeeding mothers taking lurbinectedin should:

* Consult with their healthcare provider about the potential risks and benefits of breastfeeding while taking the medication.
* Consider discontinuing breastfeeding or exploring alternative arrangements for their baby's care.
* Monitor their baby for any signs of adverse effects, such as drowsiness, lethargy, or other symptoms.

Conclusion

While the available evidence is limited, breastfeeding mothers taking lurbinectedin may need to consider the potential risks to their baby. Healthcare providers can help mothers weigh the benefits and risks and make an informed decision about breastfeeding while taking this medication.

References:

[1] FDA approval of lurbinecedin.
[2] Mechanism of action of lurbinectedin.
[3] Animal studies of lurbinectedin.
[4] Pregnancy category D for lurbinectedin.

DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/US10129259